Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

Eligibility Criteria

• 1. Subjects must be at least 18 years of age or older.
• 2. Subjects must have a diagnosis of type 1 or 2 Diabetes mellitus.
• 3. At randomization subjects must have a target diabetic foot ulcer with a minimum surface area of 1.0 cm2 and a maximum surface area of 20.0 cm2 measured post debridement with a photographic planimetry app.
• 4. The target ulcer must have been present for a minimum of 4 weeks and a maximum of 52 weeks of standard of care prior to the initial screening visit.
• 5. The target ulcer must be located on the foot with at least 50% of the ulcer below the malleolus.
• 6. The target ulcer must be full thickness on the foot or ankle that does not probe to bone.
• 7. Adequate circulation to the affected foot as documented by any of the following methods performed within 3 months of the first screening visit:
• 1. TCOM ≥30 mmHg
• 2. ABI between 0.7 and 1.3
• 3. PVR: Biphasic
• 4. TBI ˃0.6
• 5. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle
• 8. If the subject has two or more ulcers, they must be separated by at least 2 cm. The largest ulcer satisfying the inclusion and exclusion criteria will be designated as the target ulcer.
• 9. Target ulcers located on the plantar aspect of the foot must be offloaded for at least 14 days prior to randomization.
• 10. The subject must consent to using the prescribed off-loading method for the duration of the study.
• 11. The subject must agree to attend the weekly study visits required by the protocol.
• 12. The subject must be willing and able to participate in the informed consent process.
• 1. A subject known to have a life expectancy of \< 6 months is excluded.
• 2. If the target ulcer is infected or if there is cellulitis in the surrounding skin, the subject is excluded.
• 3. Presence of osteomyelitis or exposed bone, probes to bone or joint capsule on investigator's exam or radiographic evidence.
• 4. A potential subject cannot have an infection in the target ulcer or in a remote location that requires systemic antibiotic therapy.
• 5. A subject receiving immunosuppressants (including systemic corticosteroids at doses greater than 10 mg of Prednisone per day or equivalent) or cytotoxic chemotherapy is excluded.
• 6. The topical application of steroids to the ulcer surface within one month of initial screening is not permitted.
• 7. A subject with a previous partial amputation on the affected foot is excluded if the resulting deformity impedes proper offloading of the target ulcer.
• 8. If a subject has a glycated hemoglobin (HbA1c) greater than or equal to 12% taken at or within 3 months of the initial screening visit he/she is excluded.
• 9. If a subject has a serum creatinine ≥ 3.0mg/dL within 6 months of randomization he/she is excluded.
• 10. The subject is excluded if the surface area measurement of the target ulcer has reduced in size by more than 30% in the 2 weeks prior to the initial screening during the 2-week screening phase: the 2 weeks from the initial screening visit (SV1) to the TV1/randomization visit during which time the subject received SOC.
• 11. A subject with an acute Charcot foot, or an inactive Charcot foot, that impedes proper offloading of the target ulcer is excluded.
• 12. Women who are pregnant or considering becoming pregnant within the next 6 months are excluded.
• 13. A potential subject with end stage renal disease requiring dialysis is excluded.
• 14. A subject who participated in a clinical trial involving treatment with an investigational product within the previous 30 days is excluded.
• 15. A subject who, in the opinion of the Investigator, has a medical or psychological condition that may interfere with study assessments is excluded.
• 16. A subject treated with hyperbaric oxygen therapy or a Cellular and/or Tissue Product (CTP) in the 30 days prior to the initial screening visit is excluded.